Jean ZEGHONDY

Dr. Jean ZEGHONDY

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SMSara Mokbel
Sara Mokbel
GBGiuilia Baciarello
Giuilia Baciarello
PLPernelle Lavaud
Pernelle Lavaud
AOAurelius Omlin
Aurelius Omlin
FCFabio Calabrò
Fabio Calabrò
APAnna Patrikidou
Anna Patrikidou
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line. A nomogram and inflammatory prognostic index (U-IPI) were developed. The index was also tested in a control cohort of patients treated with chemotherapy only (C, n = 114). Results: The strongest predictors of OS were baseline platelet/lymphocyte (PLR) and neutrophil/lymphocyte (NLR) ratios, and lactate dehydrogenase (LDH), NLR, and albumin changes at 4 weeks. These were used to build the U-IPI, which can distinctly classify patients into good or poor response groups. The nomogram scoring is significant for PFS and OS (p < 0.001 in the D, V, and combined cohorts) for the immunotherapy (IO) cohort, but not for the control cohort. Conclusions: The lack of a baseline systemic inflammatory profile and the absence of early serum inflammatory biomarker changes are associated with significantly better outcomes on ICIs in a/mUC pts. The U-IPI is an easily applicable dynamic prognostic tool for PFS and OS, allowing for the early identification of a sub-group with dismal outcomes that would not benefit from ICIs, while distinguishing another that draws an important benefit.

29 July 2025 in Nature Communications
Verified
Journal Article
Open access
RCRoman M. Chabanon
Roman M. Chabanon
LSLiudmila Shcherbakova
Liudmila Shcherbakova
MLMagali Lacroix-Triki
Magali Lacroix-Triki
MAMarine Aglave
Marine Aglave
JZJean ZEGHONDY
Jean ZEGHONDY
SPSophie Postel-Vinay
Sophie Postel-Vinay
ADAR1 is an RNA editing enzyme which prevents autoimmunity by blocking interferon responses triggered by cytosolic RNA sensors, and is a potential target in immuno-oncology. However, predictive biomarkers for ADAR1 inhibition are lacking. Using multiple in vitro and in vivo systems, we show that BRCA1/2 and ADAR1 are synthetically lethal, and that ADAR1 activity is upregulated in BRCA1/2-mutant cancers. ADAR1 depletion in BRCA1-mutant cells causes an increase in R-loops and consequently, an upregulation of cytosolic nucleic acid sensing pattern recognition receptors (PRR), events which are associated with a tumor cell-autonomous type I interferon and integrated stress response. This ultimately causes autocrine interferon poisoning. Consistent with a key role of R-loops in this process, exogenous RNase H1 expression reverses the synthetic lethality. Pharmacological suppression of cell-autonomous interferon responses or transcriptional silencing of cytosolic nucleic acid sensing PRR are also sufficient to abrogate ADAR1 dependency in BRCA1-mutant cells, in line with autocrine interferon poisoning playing a central part in this synthetic lethality. Our findings provide a preclinical rationale for assessing ADAR1-targeting agents in BRCA1/2-mutant cancers, and introduces a conceptually novel approach to synthetic lethal treatments, which exploits tumor cell-intrinsic cytosolic immunity as a targetable vulnerability of cancer cells.

12 January 2026 in European Journal of Cancer
Verified
Journal Article
Closed access
ASAlessandra Spata
Alessandra Spata
JRJoana M. Ribeiro
Joana M. Ribeiro
PVPaolo VIGNERI
Paolo VIGNERI
Alberto ZambelliAlberto Zambelli
Alberto Zambelli
JZJean ZEGHONDY
Jean ZEGHONDY
ERElie Rassy
Elie Rassy

26 December 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
JZJean ZEGHONDY
Jean ZEGHONDY
ERElie Rassy
Elie Rassy
PLPietro Lapidari
Pietro Lapidari
RERoland Eid
Roland Eid
BPBarbara Pistilli
Barbara Pistilli
Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread, the World Health Organization (WHO) decla